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Abstract: Psoriasis is a chronic immune mediated inflammatory skin disease with a population prevalence of
2–3%. In recent years, psoriasis has been recognized as a systemic disease associated with metabolic syndrome
or its components such as: obesity, insulin resistance, hypertension and atherogenic dyslipidemia. Many bioactive
substances have appeared to be related to metabolic syndrome. Based on current literature, we here discuss the
possible role of adiponectin, leptin, ghrelin, resistin, inflammatory cytokines, plasminogen activator inhibitor 1,
uric acid, C-reactive protein and lipid abnormalities in psoriasis and in metabolic syndrome. (Folia Histochemica
et Cytobiologica 2012, Vol. 50, No. 2, 155–170)
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Introduction
Psoriasis is an immune mediated inflammatory skin
disease characterized by epidermal hyperprolifera-
tion, impaired differentiation of keratinocytes, exces-
sive angiogenesis and immunological dysfunction
[1–3]. The immunologic cells engaged in the patho-
genesis of psoriasis which have been the focus of at-
tention in recent years include not only lymphocytes
Th1, but also Th17, Th22 and regulatory T lympho-
cytes (Treg). Equally important immunological cells
are Langerhans cells and dermal dendritic cells (dDC)
(Figure 1). One of the immunological disturbances is
the predominance of Th1 response [4–6]. An elevat-
ed level of IFN-g, together with decreased levels of
IL-4, fosters the inhibition of Th2 immune response
[4, 6]. The leading role in the regulation of immune
response in psoriasis is attributed to dendritic cells
(DC). A significant increase in the number of den-
dritic cells which secrete IL-20, IL-23 and TNF-al-
pha has been observed in patients with psoriasis
[7–9]. Activated DC secrete, among others, IL-12, in-
ducing Th-1 immune response and IL-23, which fa-
vors the differentiation of naive lymphocytes into
Th17 cells [10–12]. Naive T lymphocytes differentia-
tion into Th17 cells depends on the presence of IL-1b,
IL-6, IL-21, TGF-b and IL-23 [13, 14]. An increased
percentage of Th17 lymphocytes and its cytokines
(IL-17a, IL-6) has also been observed in psoriasis
[15–21]. Studies conducted by Harper et al. [21] and
Norgales et al. [22] revealed the presence of Th 22
lymphocytes in the skin of patients with psoriasis. Dif-
ferentiation of the Th 22 lymphocytes which produce
IL-22 is induced by the presence of IL-6, TNF-alpha,
plasmacytoid dendritic cells and Langerhans cells
[23–25]. In response to IL-17 and IL-22 stimulation,
keratinocytes increase the secretion of IL-8. Further-
more, INF-g (synthesized by Th1 cells and dendritic
cells) together with IL-22, IL-6 and IL-20, enhances
the proliferation of keratinocytes [18, 26, 27]. Acti-
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vated keratinocytes secrete increased amounts of
TNF-alpha, IL-1 and IL-8, enhancing inflammation
and activation of dendritic cells. The key role in the
inhibition of inflammatory reaction and induction of
tolerance to antigen play Treg lymphocytes. Decreased
levels of Treg lymphocytes have been demonstrated in
Graft-Versus-Host Disease as well as in breast, colon
and lung cancer [28–33]. A decreased percentage or
impaired function of Treg lymphocytes, observed also
in psoriasis, may lead to an increased secretion of proin-
flammatory cytokines, which subsequently results in en-
hanced proliferation of keratinocytes [34, 35]. Distur-
bances in other tissues may occur as a result of dys-
function and changed percentage of Treg and Th1 lym-
phocytes. Cheng et al. [36] reported that a decreased
percentage of Treg lymphocytes and an increased per-
centage of Th 17 cells in patients with acute coronary
syndrome may be one of the potential causes of desta-
bilization of atherosclerotic plaques.
It is estimated that psoriasis affects 120–180 mil-
lion people worldwide [37]. A growing number of
new cases of psoriasis are reported [37, 38]. Re-
cently, psoriasis has been recognized as a systemic
disease associated with multiple comorbidities
[1, 3]. The lipid disturbances in the course of pso-
riasis have been analyzed since 1924 [39, 40]. Re-
searchers have focused their attention on comor-
bidities in psoriasis including: type 2 diabetes, ath-
erosclerosis, hypertension, myocardial infarction,
depression and obesity. Hyperuricemia in patients
with psoriasis has been noted [1, 3, 41–45]. It seems
that metabolic syndrome, for which the coexistence
of well-known cardiovascular disease risk factors
is characteristic, may be the connection between
cardiovascular complications and type 2 diabetes
in patients with psoriasis [1].
The first description of a possible coexistence of
metabolic disturbances and cardiovascular risk fac-
tors was made at the beginning of the 20th century
[46]. It was not until the end of that century when the
definition and criteria of metabolic syndrome were
introduced, being later modified [46].
Guidelines proposed by the International Diabe-
tes Federation (IDF) are the most up-to-date criteria
for diagnosing metabolic syndrome [47]. According
to the new IDF definition, for a person to be defined
as having metabolic syndrome they must have:
1. Central obesity, defined as a waist circumference
(of which the values are ethnicity-specific), plus
any two of the following factors:
a. Raised triglycerides ≥ 150 mg/dL (1.7 mmol/L)
or specific treatment for this lipid abnormality,
b. Reduced HDL cholesterol: < 40 mg/dL (1.03
mmol/L) in males, < 50 mg/dL (1.29 mmol/L) in
females, or specific treatment for this lipid ab-
normality,
Figure 1. DC — dendritic cells; MQ — macrophages, T — lymphocytes subpopulations (Th1, Th17, Th22, Treg);
HDL — high density lipoproteins cholesterol; INF-g — interferon gamma; TGFâ — transforming growth factor beta;
VEGF — vascular endothelial growth factor; TNF-a — tumor necrosis factor alpha and interleukins which are involved
in the pathogenesis of psoriasis
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c. Raised blood pressure (BP): systolic BP ≥ 130 or
diastolic BP ≥ 85 mm Hg, or treatment for pre-
viously diagnosed hypertension,
d. Raised fasting plasma glucose ≥ 100 mg/dL
(5.6 mmol/L) or previously diagnosed type 2 dia-
betes.
Comorbidity of metabolic syndrome and psoria-
sis has been stressed by many researchers. However,
the prevalence of metabolic syndrome among patients
with psoriasis varies according to the study and the
adopted criteria of metabolic syndrome. Sommer et
al. [45] reported that metabolic syndrome in patients
with psoriasis was at least twice as common as in
a control group. The results of this study are consistent
with data published by Love et al. [48]. However, in
both studies, different criteria of metabolic syndrome
were used [45, 48]. Love et al. [48] found the preva-
lence of metabolic syndrome to be 40% among adult
patients with psoriasis and 23% in a control group.
In another study performed on 338 patients with
plaque psoriasis and 334 patients with other skin dis-
eases, a higher prevalence of metabolic syndrome was
observed in the first group (30.1% and 20.6% respec-
tively). Moreover, the prevalence of metabolic syn-
drome correlated with the duration of psoriasis [44].
Similar results were obtained by Nisa et al. [49] who
observed metabolic syndrome in 28% of patients with
psoriasis. Mebazaa et al. [50] also observed a higher
prevalence of metabolic syndrome in patients with
psoriasis than in a control group, although it was not
statistically significant. It is worth noting that meta-
bolic syndrome has also been observed in patients with
psoriatic arthritis. Raychaudhuri et al. [51] showed
that as many as 58% of men and 60% of women with
psoriatic arthritis fulfilled the criteria of metabolic syn-
drome. Additionally, the association between single
features of metabolic syndrome and psoriasis has also
been investigated [43, 52].
The exact mechanism for the development of
metabolic syndrome in patients with psoriasis is yet
to be fully understood. Some researchers have sug-
gested that psoriasis predisposes to the development
of obesity or hypertension due to a stressful life, re-
duced physical activity, or greater tobacco and/or al-
cohol consumption [41].
Currently, it is considered that insulin resistance
and abdominal obesity play vital roles in the patho-
genesis of metabolic syndrome [46, 47]. The possible
comorbidity of psoriasis and obesity has been suggest-
ed by many authors. It has been reported that obesity
is more common in patients with psoriasis [53, 54].
Naldi et al. [55] demonstrated that the risk of devel-
oping psoriasis is related to BMI (body mass index),
whereas the risk is higher in obese people.
Nowadays, white fat tissue is considered to be an
active endocrine organ which has an effect on many
metabolic processes. Fat tissue cells (adipocytes) can
produce and secrete numerous bioactive elements
known as adipokines including many cytokines, hor-
mones and growth factors [56, 57]. They are involved
in preserving homeostasis, regulating the glucose and
lipid metabolism and blood pressure. Adipokines also
take part in regulating the sensitivity to insulin and
they are involved in inflammatory and immune pro-
cesses [57]. Therefore, taking numerous functions into
consideration, adipokines are under constant scruti-
ny. The contribution of adipokines to metabolic syn-
drome has also been reported [58].
The IDF has suggested using a so called ‘platinum
standard’ in research studies related to metabolic syn-
drome which includes additional metabolic criteria such
as: leptin, adiponectin, apolipoprotein B (Apo B), low
density lipoprotein (LDL), proinflammatory cytok-
ines and C-reactive protein (CRP) levels as well as
markers of prothrombotic state [47].
The aim of this study is to review current litera-
ture data concerning the biochemical markers of
metabolic syndrome in patients with psoriasis.
Adiponectin
Adiponectin is a polypeptide composed of 244 ami-
no acids. It is synthesized mostly by adipocytes [59].
It has been proved that the gene which codes adi-
ponectin (AMP1) is localized on chromosome 3q27.
Moreover, it has been found that the locus of prone-
ness to type 2 diabetes is localized on the same chro-
mosome [60]. Adiponectin can occur as an oligomer-
ic complex as well as a high molecular weight adi-
ponectin — HMV which is its most active form [61].
It is recognized that adiponectin has anti-inflam-
matory properties: it negatively regulates synthesis of
TNF-alpha in fat tissue, and inhibits secretion of this
cytokine by heart muscle cells. Additionally, adiponec-
tin inhibits production of IL-8, vascular adhesion
molecule-1 (VCAM-1), and reactive oxygen species
(ROS) in endothelial cells. It also stimulates synthe-
sis of IL-10 [59, 62].
This protein has also a protective antiatherogenic
effect which arises through decreasing monocyte ad-
hesion to the endothelium and reducing synthesis of
VCAM-1, intercellular adhesion molecule-1 (ICAM-1)
and E-selectin [59, 63]. Adiponectin increases the syn-
thesis of nitric oxide in endothelial cells by intensify-
ing the synthesis of mRNA for endothelial nitric ox-
ide synthase (eNOS), subsequently relaxing smooth
muscles [59, 63]. In vitro studies on cell cultures show
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that adiponectin has an anti-apoptotic effect on heart
muscle cells and fibroblasts [64]. Therefore, some au-
thors recommend regarding its decreased blood con-
centration as a risk factor for cardiovascular disease [65].
It is worth noting that low plasma or serum levels
of adiponectin have been found in obesity, type 2 di-
abetes, coronary disease, hypertension and non-alco-
holic fatty liver disease in obese patients [59, 66, 67].
It is interesting that in other inflammatory diseases
such as lupus erythematosus, cystic fibrosis and type
1 diabetes, circulating levels of adiponectin are ele-
vated [68]. These observations may suggest that adi-
ponectin levels are under the control of other regula-
tory mechanisms in chronic inflammatory diseases
related to obesity [63].
Considering the fact that adiponectin is related to
metabolic syndrome [62], which can coexist with pso-
riasis, it cannot be excluded that this protein plays
a role in pathophysiological processes in psoriasis.
Several studies have reported decreased circulat-
ing levels of adiponectin in patients with psoriasis
compared to a control group [69, 70]. Additionally,
researchers have determined that adiponectin con-
centration levels are negatively correlated with psori-
asis severity measured by PASI (Psoriasis Area and
Severity Index) as well as with the plasma concentra-
tion of TNF-alpha [69]. Shibata et al. [71] demon-
strated a significant increase of serum adiponectin
concentration in patients with psoriasis and psoriatic
arthritis who were treated either with anti-TNF-al-
pha agents or with narrowband UVB. Moreover, they
showed that an increase of adiponectin concentration
was associated with a decrease of IL-6 concentration.
Kaur et al. [72] investigated the correlation be-
tween adiponectin, body weight and oxidative stress.
Obese patients with psoriasis had a significantly higher
concentration of IL-6, which additionally was nega-
tively correlated with adiponectin concentration. Only
in obese psoriatic patients was the glutathione redox
ratio (GHS), which is a marker of oxidative stress,
significantly higher, and it correlated negatively with
the concentration of adiponectin.
It seems that obesity in psoriatic patients could be
connected to decreased protective influence of adi-
ponectin and with enhanced systemic inflammatory
process and oxidative stress [72]. Coimbra et al. [73]
achieved similar results. They found that the concen-
tration of circulating adiponectin was significantly lower
in psoriatic patients with BMI > 30 compared to pso-
riatic patients with BMI < 25 and to a control group.
The results of this study may point to a correla-
tion between psoriasis and obesity, and its plausible
influence on lowering adiponectin concentration,
which correlated negatively with BMI [73].
Leptin
Leptin is a polypeptide composed of 166 amino acids
of molecular mass 14kDa. It is coded by obesity gene
localized on the 7q31 chromosome. [57, 63, 74, 75].
Most of this protein is synthesized in adipocytes,
though some minor quantities are found in placenta,
ovaries, skeletal muscles, stomach, liver and pituitary
gland [60, 72].
The main role of leptin is to regulate food con-
sumption through a neuroendocrine system by reduc-
ing appetite [57, 76]. It has also an effect on immuno-
logical processes. Moreover, it is involved in wound
healing and hair growth [76, 77].
Interestingly, people with leptin deficiency are very
obese [63]. On the other hand, obese patients have
higher leptin concentration. However, they do not
react to higher leptin levels by a decrease in their ap-
petite [76]. Therefore, it is supposed that obese pa-
tients are resistant to leptin, just as in type 2 diabetes,
where insulin resistance is observed [63, 76, 78]. Fur-
thermore, hyperleptinemia caused by obesity is an im-
portant risk factor leading to the development of
type 2 diabetes [79].
Hyperleptinemia may lead to the development of
atherosclerosis in obese patients [80]. Other authors
suggest that leptin is involved in the formation of
atheromatous plaques [81].  The  suggestion has been
made to regard elevated leptin levels as an indepen-
dent factor indicating future coronary disease and
cardiovascular complications [82].
An assumption, based on the articles mentioned
above, can be made that leptin is correlated with
metabolic syndrome, and moreover it may be in-
volved in the pathophysiology of psoriasis. Wang
et al. [74] found higher serum leptin levels in wom-
en and men with psoriasis compared to a control
group. Higher plasma leptin levels in patients with
psoriasis were also noted in a Japanese population
[69]. Furthermore, higher leptin concentration was
associated with higher PASI, although it was not
statistically significant [69]. In another study, sig-
nificantly elevated serum leptin concentration was
found in female patients with psoriasis, whereas
male patients with psoriasis showed a trend towards
higher values compared to the control groups of
the same gender. Furthermore, patients with BMI >
> 30 had significantly higher leptin concentration
than the groups with lower BMI, as well as the con-
trol group. However, it is worth noting that as many
as 58% of patients with the highest BMI were wom-
en [73]. A study conducted by Johnston et al. [83]
on 30 obese patients with plaque psoriasis and
a control group (BMI 30.5, 30.8 respectively) did
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not prove any statistically important differences in
the serum levels of leptin and its soluble receptors
compared to the control group. However, the au-
thors proved that there was a significant correla-
tion between BMI, waist circumference and leptin
concentration [83]. Therefore, it seems that leptin
concentration is related to BMI, and so hyperlep-
tinemia in patients with psoriasis may be correlat-
ed with obesity [73].
It has been proposed that leptin, through promot-
ing synthesis of Th1 cytokines and inhibiting synthe-
sis of Th2, might be involved in the pathogenesis of
psoriasis [73, 74]. Considering that inflammation
mediated by Th1 lymphocytes is one of the factors
leading to the development of atherosclerosis and
coronary disease [84], it seems that leptin may be
a connection between psoriasis and cardiovascular
complications [85].
Resistin
Resistin is a polypeptide composed of 108 amino ac-
ids of molecular weight 12.5kDa [86]. High cystein
content is a characteristic feature of resistin [57]. This
adipokine is synthesized mostly by macrophages and
monocytes contained in fat tissue [83, 87, 88]. Addi-
tionally, resistin is produced in bone marrow, placen-
ta, pancreas, joint fluid, synovial tissue and the pe-
ripheral blood [89–92].
There have been suggestions that resistin plays
a role in inflammation. It has been proved that pro-
inflammatory cytokines such as TNF-alpha, IL-6,
IL-1beta and lipopolysaccharides are able to increase
the expression of resistin in peripheral blood mono-
nuclear cells (PBMCs); however, resistin itself is ca-
pable of inducing the synthesis of TNF-alpha or
IL-12 [63, 93, 94].
It is worth noting that resistin owes its name to
the observed influence of this protein on insulin re-
sistance [95]. However, resistin’s role in obesity and
insulin resistance is not yet fully understood [96]. Mice
which were given resistin had a lowered sensitivity to
insulin. Another study has reported higher resistin
levels in obese mice [97, 98].
Different results were described in a study in which
resistin concentration was measured and compared
in obese patients, obese patients with type 2 diabetes,
and patients with normal body weight. A negative cor-
relation was found between the concentration of resis-
tin and sensitivity to insulin only in the patients with
normal body weight [99]. Another study revealed that
synthesis of resistin by fat tissue in morbidly obese pa-
tients was significantly higher compared to slim peo-
ple; however, no correlation with BMI was found [100].
Different results observed in humans and mice might
suggest that resistin in the human body is synthesized
mostly by non-adipose components of fat tissue, which
would explain the observed phenomenon [86].
A link between resistin and cardiovascular com-
plications has been emphasized [86]. Significantly el-
evated serum resistin levels in patients with type 2
diabetes  during acute STEMI (acute ST segment el-
evation myocardial infarction) has been described
compared to patients with acute STEMI but without
type 2 diabetes, or to a control group [101]. This sug-
gests that resistin may be involved in the pathogene-
sis of metabolic syndrome.
Elevated resistin levels have been found in patients
with psoriasis, and moreover its concentration corre-
sponded with PASI index [73, 83, 85]. It is recognized
that obesity is associated with chronic inflammation,
which is characterized by elevated proinflammatory
cytokine synthesis. Considering this fact, and the abil-
ity of resistin to induce synthesis of pro-inflammato-
ry cytokines, it cannot be excluded that resistin is in-
volved in the development of metabolic syndrome
observed in patients with psoriasis [73, 85, 102].
Ghrelin
Gherlin is a peptide hormone similar in structure to
motilin [103]. It was discovered by Kojima et al. [103]
during their search for the natural ligand of a growth
hormone secretagogues-receptor (GHS-R). Ghrelin
is composed of 28 amino acids. Two forms of ghrelin
are distinguished: acylated and unacylated [103–105].
The main source of ghrelin is a mucous membrane of
the stomach, but ghrelin is also synthesized in many
other organs [106]. Secretion of ghrelin increases when
energy balance is negative, which leads to increased
appetite and decreased energy expenditure [106].
Recently, it has been suggested that ghrelin takes
part in the development of metabolic syndrome [107].
Ghrelin concentration decreases in conditions such
as obesity, type 2 diabetes and hypertension [108, 109].
We can find no studies covering the role of ghre-
lin in psoriasis. However, some authors have suggest-
ed that if ghrelin plays a role in the pathogenesis of
obesity, which is one of the elements of metabolic syn-
drome, it can also take part in the pathogenesis of
psoriasis [102].
Interleukin-6 (IL-6)
IL-6 is one of the most important inflammatory cy-
tokines. It is synthesized by various cells such as:
monocytes, fibroblasts, endothelial cells and adipo-
cytes upon exposure to appropriate stimuli [63, 110].
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Particularly interesting is the study conducted by Fujish-
ima et al. [111]. The authors showed that IL-17F was
able to induce synthesis of IL-6, both in normal hu-
man epidermal keratinocytes (NHEKs) and in mouse
skin. It is worth noting that NHEKs expressed much
higher amounts of IL-6 after stimulation by IL-17F
than by IL-17A or TNF-alpha. The authors suggest
that IL-17F may be a crucial cytokine that induces IL-6
expression in NHEKs [112]. IL-6 acts as a chemotac-
tic factor for T cells, thus it stimulates the migration of
T cells into the epidermis. IL-6 influences the growth
and differentiation of dermal and epidermal cells [112]
and is also involved in hematopoiesis [112].
It has been proved that the synthesis of IL-6 in fat
tissue and its circulating levels are positively corre-
lated with obesity, inadequate glucose tolerance, and
resistance to insulin [113, 114]. Moreover, a reduc-
tion of body weight is associated with reduced con-
centration of this interleukin, as well as reduction of
its synthesis in fat tissue [114]. Esteve et al. [115] found
that serum IL-6 concentration was negatively corre-
lated with sensitivity to insulin, whereas it showed
a positive correlation with BMI, blood pressure val-
ues and triglyceride levels. It was also indicated that
IL-6 concentration was positively correlated with in-
tima media thickness. Nishida et al. [116] suggested
considering serum concentration of IL-6 as a marker
of processes which might lead to early arterial alter-
ations in men.
Significantly increased serum levels of IL-6 have
been reported in psoriatic patients. [73]. A positive
correlation between elevated IL-6 levels and PASI has
also been proved [73]. It is worth noting that higher
IL-6 levels and its receptor have been observed in
psoriatic plaques [117].
It is thought that obesity has a negative influence
on the course of psoriasis [118], due to the increased
synthesis of leptin, IL-6, TNF-alpha and reduced pro-
duction of adiponectin by fat tissue [73]. A negative cor-
relation between plasma IL-6 and adiponectin levels in
obese patients has been observed [72]. Kaur et al. [72]
noted a statistically significant elevation of IL-6 con-
centration in obese patients with psoriasis compared
to a control group. In patients with psoriasis and with
normal body weight, the plasma concentration of
IL-6 was elevated in relation to the control group,
although it was not significant. Johnston et al. [83]
came to a similar conclusion. They observed elevated
levels of IL-6 in obese patients with psoriasis.
Another study found a positive correlation be-
tween plasma concentration of IL-6 and the oxidized
LDL-b2-glycoprotein complexes (oxLDL-b2-GPI) in
patients with psoriasis [119]. Furthermore, a concen-
tration of oxidized LDL and oxidized LDL-b2-glyco-
protein complexes showed a positive correlation with
BMI. According to the authors, the correlation between
oxLDL-b2-GPI, IL-6 and BMI may suggest a connec-
tion between LDL oxidation and inflammation, includ-
ing the inflammatory process observed in obesity.
Interleukin-8 (IL-8)
IL-8 is a chemokine involved in many pathological
processes. The main function of IL-8 is a chemotaxis
of neutrophils to a place affected by inflammation. It
also induces antibacterial features of neutrophils.
Apart from that, IL-8 induces angiogenesis and in-
fluences other cells, which take part in inflammatory
response including: T lymphocytes, natural killer cells
(NK) and basophils, and it is also chemotactic towards
keratinocytes [112, 120, 121].
Authors have drawn attention to the fact that IL-8
plays a role in the pathogenesis of type 2 diabetes
and of atherosclerosis [122]. Significantly higher cir-
culating levels of IL-8 have been found in patients
with heart failure and metabolic syndrome compared
to patients with heart failure without metabolic syn-
drome [123]. It has been proved that proinflammato-
ry cytokines such as TNF-alpha, IL-1 and CRP in-
duce synthesis of IL-8 in human adipocytes [124, 125].
Kobashi et al. [125] stated that IL-8 reduces phos-
phorylation of AKT by insulin in human adipocytes,
which can induce resistance to insulin.
A significantly elevated concentration of IL-8 has been
found in patients with acute psoriasis [126]. Another study
showed a higher IL-8 plasma concentration in patients
with psoriasis, which decreased with the improvement of
clinical appearance [127]. In a study performed on a Jap-
anese population, a significant elevation of serum IL-8
levels in patients with psoriasis was found, although
a correlation with PASI was not observed [128]. The au-
thors pointed out enhanced local synthesis of mRNA for
IL-8 or its receptors in psoriatic plaques [126, 129].
To date, there have been no studies evaluating the
correlation between IL-8 levels and the development
of metabolic syndrome in patients with psoriasis. How-
ever, when the role of this cytokine in the pathogene-
sis of insulin resistance, type 2 diabetes or atheroscle-
rosis [122, 125, 130] is taken under consideration, it
cannot be excluded that elevated circulating levels of
IL-8 in patients with psoriasis may contribute to the
maintenance of the inflammation, which plays a vital
role in the pathogenesis of metabolic syndrome.
Tumor necrosis factor-alpha (TNF-alpha)
TNF-alpha is a proinflammatory cytokine produced
by various cells such as: lymphocytes, monocytes/mac-
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rophages, mast cells and NK cells [63]. TNF-alpha
influences the proliferation, activation or differenti-
ation of many cells [131]. TNF-alpha also increases
the synthesis of some proinflammatory cytokines,
growth factors and adhesive molecules [112]. Several
studies have shown that TNF-alpha may impair insu-
lin signaling in many cells such as liver, adipose tissue
or skeletal muscles [132–134]. This cytokine may also
lead to insulin resistance through the inhibition of
phosphorylation of tyrosine receptor and insulin re-
ceptor substrate 1 (IRS-1) [39]. It has been observed
that obese mice did not develop insulin resistance if
TNF-alpha activity had been blocked [135].
Increased levels of TNF-alpha have been report-
ed in obese patients [136]. A positive correlation be-
tween TNF-alpha and BMI has also been reported
[137]. Recently, it was reported that elevated plasma
levels of TNF-alpha are associated with left ventricu-
lar diastolic dysfunction, which is one of the earliest
manifestations of left ventricular dysfunction due to
diabetes mellitus [138], while administration of
TNF-alpha inhibitors leads to an increase of HDL
levels [39]. It has been stressed that TNF-alpha is involved
in the pathogenesis of metabolic syndrome [1, 46].
TNF-alpha is one of the major cytokines in the
pathogenesis of psoriasis. Elevated levels of this cy-
tokine have been reported in many studies in patients
with active psoriasis [112, 139]. A positive correlation
between serum levels of TNF-alpha and PASI has
been noted [112]. It has been shown that TNF-alpha
levels negatively correlated with plasma levels of ad-
iponectin, while this cytokine did not show any corre-
lation with leptin levels in patients with psoriasis [69].
In contrast to other adipokines, TNF-alpha is syn-
thesized not only within adipose tissue. Therefore,
elevated levels of TNF-alpha, which are observed in
the serum of patients with psoriasis, may also result
from the severe inflammatory process in psoriasis as
well as from the contribution of other cells in the syn-
thesis of this cytokine [63]. It is interesting that sever-
al research studies have shown increased body weight
in patients with psoriasis after therapy with anti-TNF-
-alpha agents [140–142].
Interleukin-17 (IL-17)
IL-17 belongs to the cytokines produced by Th 17
cells [143]. This cytokine leads to the mobilization of
neutrophils [144], and stimulates secretion of IL-6,
IL-8, prostaglandin E2 (PGE2) and granulocyte-
macrophage colony-stimulating factor, in fibroblastic,
epithelial and endothelial cells [145–147].  IL-17 induc-
es the expression of ICAM 1 on fibroblasts [146] and it
enhances the maturation of dendritic cells [147, 148].
Recently, IL-17 has been found to take part in the
pathogenesis of multiple sclerosis, inflammatory bowel
diseases and rheumatoid arthritis, as well as psoriasis [144].
Elevated levels of IL-17 have been reported in
obese patients [149, 150]. However, it has not been
elucidated whether IL-17 influences metabolism and
leads to the development of obesity, or whether the
elevated synthesis of this cytokine results from inflam-
mation observed in the course of obesity [150]. It has
also been reported that T cells localized in adipose
tissue produce IL-17 [150]. Moreover, this study
showed that IL-17 regulates adipogenesis and glucose
metabolism [150]. Significantly elevated serum levels
of IL-17 have been observed in patients with type 2
diabetes [151].
It has also been shown that patients with acute
coronary syndrome have significantly higher levels of
IL-17 than patients with stable angina or non-cardi-
ac chest pain [152]. In other studies, elevated plasma
or serum levels of IL-17 were also reported in pa-
tients with non stable angina or in patients with acute
myocardial infarction [153, 154]. It has been suggest-
ed that increased levels of IL-17 may be associated
with ischemic heart disease [154].
It is interesting that decreased serum levels of IL-17
were observed in patients with metabolic syndrome
compared to a control group [155]. It is worth noting
that a decline in IL-17 levels was associated with an
increase of TGFb levels [155]. On the other hand,
the association between IL-17 and heart disease, hy-
pertension or type 2 diabetes suggests the possible
role of this cytokine in the pathogenesis of metabolic
syndrome [155].
Nowadays, it is known that IL-17 plays a vital role
in the pathogenesis of psoriasis [156]. Fujishima et
al. [111] demonstrated that CD4+ T lymphocytes sub-
sets secreted higher amounts of IL-17F in psoriatic
lesions than in non-lesional skin. It has also been
shown that IL-17F is a strong inducer of IL-6 expres-
sion in keratinocytes. Thus, it was suggested that the
IL-17F/IL-6 axis might enhance inflammation in pso-
riatic skin [111]. A positive correlation between ele-
vated serum levels of IL-17 and PASI has been re-
ported [128]. Moreover, biologic agents that inhibit
the function of Th 17 cells lead to a decrease of IL-17
production and to an improvement in the clinical con-
dition of patients [157]. However, Nakajima et al.
[143] reported no detectable serum levels of IL-17,
either in patients with psoriasis or in a control group.
So far, there have been no studies which determine
the correlation between circulating levels of IL-17 and
the occurrence of metabolic syndrome in patients with
psoriasis.
Considering the fact that IL-17 is involved in the
pathogenesis of psoriasis and atherosclerosis, it has
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been suggested that the possible link between psoria-
sis and one of the metabolic syndrome complications
such as myocardial infarction, might be IL-17 [152].
Interleukin-18 (IL-18)
IL-18 exerts its activity on innate immunity but also
on Th1 and Th2 driven immune response [158]. To-
gether with IL-12, it triggers the synthesis of INFg by
T helper and T cytotoxic and NK cells. As a result,
INFg leads to a decreased Th2 response and an in-
creased Th1 response [159]. IL-18 has been reported
to induce the production of IL-4, IL-13 by basophils,
mast cells, T cells and NK cells [158]. Moreover, IL-18
is synthesized by adipocytes and resident macroph-
ages within adipose tissue [160, 161]. Production of
this cytokine has also been shown within atheroscle-
rotic plaques [162]. According to some authors, IL-18
may be responsible for the instability of atheroscle-
rotic plaques [163].
In a study of 10,600 European men, significantly
increased baseline plasma levels of IL-18 were report-
ed among patients who developed a coronary event
during the study compared to those who did not [164].
It was suggested that plasma levels of IL-18 might be
considered as an independent predictor of future cor-
onary events [164, 165]. However, Weiss et al. [160]
reported that expression levels of IL-18 in adipose
tissue were significantly lower in patients with car-
diovascular disease compared to those without it.
An elevated concentration of serum IL-18 is as-
sociated with an increased risk of the development of
type 2 diabetes, both in middle-aged men and women
[166]. Hung et al. [167] demonstrated in a large popu-
lation study that serum levels of IL-18 correlated with
IL-6 and C-reactive protein. Moreover, the concen-
tration of IL-18 correlated with waist circumference,
triglyceride, blood pressure, and insulin levels, both in
men and women. An inverse correlation was observed
between IL-18 and HDL levels. According to the au-
thors, IL-18 might be involved in the pathogenesis of
metabolic syndrome. Another study reported an asso-
ciation between elevated plasma levels of IL-18 and
higher metabolic syndrome prevalence [168].
Increased synthesis of IL-18 has also been report-
ed in psoriasis [158]. Overproduction of IL-18 mRNA
levels and IL-18 receptor mRNA was observed with-
in skin lesions in patients with psoriasis compared to
a healthy control group [169]. Increased plasma and
serum levels of IL-18 were revealed in patients with
psoriasis compared to a control group [170–172]. An
association between concentration of IL-18 and PASI
index has also been reported [171, 173].
To date, there have been no studies evaluating the
association between IL-18 levels and metabolic syn-
drome prevalence in psoriasis. On the other hand,
the role of IL-18, both in the pathogenesis of psoria-
sis and metabolic syndrome, has been reported [112,
158, 167, 169, 174]. Therefore, given the higher prev-
alence of the components of metabolic syndrome such
as hyperlipidemia, hypertension and type 2 diabetes in
patients with moderate to severe psoriasis, it might be
suspected that IL-18 is involved in the development of
metabolic syndrome in patients with psoriasis. How-
ever, this hypothesis requires further studies [45].
Interleukin-23 (IL-23)
IL-23 is synthesized by antigen presenting cells, mainly
by dendritic cells [175]. It plays a vital role in the type 1
T cells immune response and furthermore it triggers
cytotoxicity of lymphocytes CD8+. IL-23 induces de-
velopment of Th 17 cells which produce IL-17, IL-22
and TNF-alpha [175]. It is considered that IL-23 is
a potent stimulus which leads to production of IL-17
[176, 177]. IL-23 has been demonstrated to be a key
cytokine in the inflammation in peripheral tissues
[178]. Increased concentration in IL-23 has been ob-
served in obese women [149]. Recently, it was report-
ed that IL-23/Th17 pathway is involved in the patho-
genesis of psoriasis and numerous inflammatory dis-
eases [179].
The results of studies evaluating the levels of IL-23
in patients with psoriasis are ambiguous. Nakajima
et al. [143] demonstrated undetectable serum levels
of IL-23, both in patients with psoriasis and in a con-
trol group. But Coimbra et al. [127] reported signifi-
cantly elevated serum levels of IL-23 in patients with
psoriasis, which decreased after three weeks of PUVA
or NB-UVB therapy.
Monoclonal antibodies derived against IL-12/
/IL-23 have been observed to lead to a decrease of
IL-17 levels [152]. Taking into consideration the fact that
inhibiting IL-17 in mice leads to a reduction of ath-
erosclerotic plaque size, it is suggested that in humans,
a reduction of IL-17 production may inhibit the de-
velopment of atherosclerosis [152]. Thus it may be
suspected that the IL-23/IL-17 cytokine axis is in-
volved in the pathogenesis of cardiovascular disor-
ders. However, precise recognition of its role needs
further research.
Interleukin-1 beta (IL-1 beta)
IL-1 beta belongs to the IL-1 family. Due to its proin-
flammatory properties, ability to induce synthesis of
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other cytokines by T cells and to activate neutrophils,
monocytes, eosinophils or basophils [112], IL-1 beta
is involved in the pathogenesis of a number of au-
toimmune and inflammatory diseases [180].
Recently, there has been a focus on the link be-
tween IL-1 beta and metabolic disorders including
metabolic syndrome [181]. Increased expression of
IL-1 beta in adipose tissue of obese subjects has been
reported [182]. It was revealed that patients with ele-
vated plasma levels of IL-6 and with detectable lev-
els of IL-1 beta had a roughly three-fold higher risk
of developing type 2 diabetes than that of a control
group. Patients who had only elevated levels of IL-6
and undetectable levels of IL-1 beta did not have an
increased risk of type 2 diabetes compared to the con-
trol subjects [183]. The authors suggested that inter-
action between IL-6 and IL-1 beta may be involved
in the pathogenesis of type 2 diabetes [183].
Jager et al. [181] demonstrated that IL-1 beta in-
hibits insulin-induced glucose transport in adipocytes
by decreasing an expression of insulin receptor sub-
strate 1 (IRS-1). According to the authors, IL-1 beta,
which is produced by adipose tissue-resident mac-
rophages, can impair adipocytes’ biology and lead to
the development of insulin resistance.
An attempt has been made to evaluate the role of
IL-1 beta in the pathogenesis of psoriasis. Elevated
levels of IL-1 beta have been reported in superna-
tants of monocyte cultures obtained from patients
with psoriasis [112]. It was also noted that produc-
tion of IL-1 beta by PBMCs correlated with psoriasis
severity [112]. The study conducted by Johnston at
al. [83] provided some interesting data. The authors
demonstrated that obese patients with psoriasis had
significantly higher serum concentration of IL-1 beta
compared to the control group. However, no signifi-
cant changes in the serum levels of IL-1 beta after
the course of UVB treatment were noted [83].
Plasminogen activator inhibitor 1 (PAI-1)
PAI-1 is a potent inhibitor of fibrinolysis which inter-
acts both with tissue-type (t-) and urokinase-type
(u-) plasminogen activator which leads to inhibition of
the conversion of plasminogen to plasmin [184, 185].
PAI-1 is a single chain glycoprotein and belongs
to the family of serine protease inhibitors. PAI-1 can
be synthesized by a variety of cells including endot-
helial cells, hepatocytes, smooth muscle cells, adipo-
cytes, and platelets [185].
Recently, it was noted that elevated levels of PAI-1
were related to abdominal obesity, insulin resistance,
hypertriglyceridemia, thrombosis and cardiovascular
disease [186, 187]. Elevated levels of PAI-1 correla-
ted also with the development of type 2 diabetes [188].
Therefore, a prothrombotic state is implicated in the
pathogenesis of metabolic syndrome [47].
Increased plasma levels of PAI-1 have been report-
ed in patients with psoriasis, and the concentration
of PAI-1 became lower in the course of the therapy
[189]. In another study, elevated PAI-1 levels and re-
duced levels of t-PA were observed in patients with
psoriasis [190]. A positive correlation between ele-
vated levels of homocysteine and PAI-1 has been dem-
onstrated in psoriatic patients [190]. It is worth not-
ing that homocysteine may alter PAI-1 binding to
endothelium [190].
These findings are particularly interesting because
they stress the presence of fibrinolytic disturbances
in psoriasis.
It is considered that PAI-1 is a risk factor for car-
diovascular disease and type 2 diabetes [191–195].
Therefore, it cannot be excluded that fibinolytic dis-
turbances observed in psoriasis are involved in the
development of cardiovascular complications in these
patients.
Uric acid
Recently, it was noted that elevated serum levels of
uric acid are associated with factors that contribute
to metabolic syndrome, including: hypertriglyceri-
demia, obesity, hypertension and diabetes [196–199].
An attempt was made to evaluate whether the con-
centration of uric acid correlated with a single or in-
creased number of elements which contribute to met-
abolic syndrome. In a large population study, it was
demonstrated that increased serum levels of uric acid
correlated with hypertriglyceridemia, abnormal waist
circumference, high blood pressure and decreased
HDL level. After controlling the results with BMI,
elevated serum levels of uric acid still showed a cor-
relation with hypertriglyceridemia, increased blood
pressure and with decreased HDL levels [200].
Hyperuricemia has also been demonstrated in
patients with psoriasis. It is thought that hyperurice-
mia may result from accelerated epidermal turn-over
[201]. Studies conducted in the second half of the 20th
century which aimed to determine the relationship
between hyperuricemia and psoriasis, produced con-
flicting results [201].
It has been demonstrated that an elevated serum
concentration of uric acid is positively correlated with
PASI, BMI and total body surface area compared to
a normouricemic group [201]. In another study, an in-
creased concentration of uric acid was found in pa-
tients with psoriasis compared to two other groups (pa-
tients with skin disorders other than psoriatic lesions,
164 A Gerkowicz et al.
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2012
10.5603/FHC.2012.0025
www.fhc.viamedica.pl
and a control group). After 12 weeks of therapy, a sig-
nificant reduction of mean uric acid level was observed
in patients with psoriasis. Furthermore, increased con-
centration of uric acid was accompanied by increased
serum level of C-reactive protein. [202]. Hyperurice-
mia has also been reported in psoriatic arthritis [203].
It has been suggested that serum uric acid should
be monitored in patients with psoriasis and metabol-
ic syndrome [200–202]. However, a prospective study is
required in order to determine if the prevention or treat-
ment of hyperuricemia may affect the development of
metabolic syndrome or the course of psoriasis.
Lipid abnormalities
Different lipid abnormalities are included in the
pathogenesis of metabolic syndrome. One of them is
an elevated concentration of Apo B. It is recognized
that Apo B is responsible for the accumulation of LDL
cholesterol within the endothelium; therefore, it is
involved in the initiation of atherosclerotic plaques
formation. Moreover, increased levels of Apo B are
connected to an increased risk of development of ath-
erosclerosis [204]. To date, few studies have demon-
strated elevated levels of Apo B in psoriasis [39, 204].
However, there have also been studies which did not
reveal any differences in Apo B concentration be-
tween patients with psoriasis and the healthy control
group [39]. Increased levels of apolipoprotein A1
(Apo A1) have also been reported in patients with
psoriasis [205]. It has been shown that an increased
concentration of Apo A1 increases the risk of ath-
erosclerosis [206]. Particularly interesting is the study
conducted by Wilhelm et al. [207]. They observed that
substitution of Apo A-1 to hypercholesterolemic mice
lacking high density lipoprotein apolipoprotein A1
(HDL Apo A1) or LDLr(-/-) (low density lipoprotein
receptor), apoA-I(-/-) (DKO) resulted in an increased
percentage of Treg lymphocytes [207]. Other commonly
reported lipid abnormalities in patients with psoriasis
include: elevated LDL, total cholesterol and triglycer-
ide levels [205, 208–211] as well as decreased HDL lev-
els [211, 212]. The study published by Tekin et al. [208]
indicates that oxidized low-density lipoprotein is accu-
mulated in psoriatic skin lesions.
It is worth noting that, both in psoriasis and ath-
erosclerosis, HDL becomes dysfunctional and has
proinflammatory properties [213]. Additionally,
CD209+/CD163+ dermal macrophages which are ca-
pable of engulfing oxidized lipids have been identi-
fied in psoriatic tissue. Moreover, it has been demon-
strated that TPH-1 macrophages stimulated by a com-
ponent of minimally oxidized LDL express IL-1, 6,
15, 17, 23, VEGF and cathelicidin, all of which are
involved in pathogenesis of psoriasis [213]. This study
indicated that host lipids and dermal macrophages
are involved in the pathogenesis of psoriasis.
It is thought that lipid abnormalities are involved
in the pathogenesis of psoriasis. Moreover, they are
considered as factors that may lead to increased mor-
tality due to cardiovascular complications. There have
been many publications devoted to the role of lipids
in psoriasis [39, 204], therefore in this review they will
not be discussed in detail.
C-reactive protein (CRP)
A number of studies have demonstrated a link be-
tween the concentration of C-reactive protein and
cardiovascular disease, BMI, waist to hip ratio, hy-
pertriglyceridemia, increased levels of glucose, abnor-
mal blood pressure, and insulin resistance [214–216].
Several studies have reported a correlation be-
tween increased levels of CRP and PASI [73, 217, 218].
Coimbra et al. [219] determined a prevalence of car-
diovascular risk factors in patients with psoriasis. They
demonstrated significantly higher levels of CRP com-
pared to a control group. Although CRP concentra-
tion was reduced after the phototherapy, it still re-
mained higher than in the control group. Consider-
ing these results, the authors suggested that in psori-
asis there might be an inflammatory process which
persists even after the therapy, and may lead to the
development of atherogenic changes [219]. A posi-
tive correlation between elevated serum levels of high
sensitivity of CRP (hs-CRP) and the degree of arterial
stiffness in patients with psoriasis was reported in an-
other study [220]. Moreover, increased concentration
of hs-CRP seems to be an independent predictor of
arterial stiffness. It has been suggested that the inflam-
matory process in psoriasis, which is characterized by
elevated levels of CRP, is connected to increased arte-
rial stiffness and premature development of athero-
sclerosis. These findings provide further evidence of
a link between inflammation and cardiovascular disea-
ses in patients with psoriasis [220]. This study is consis-
tent with the research published by Ludwig et al. [221],
which reported an increased prevalence and severity
of coronary artery calcification as an indicator for car-
diovascular disease in patients with psoriasis.
Conclusions
A large number of recently conducted studies have
revealed the link between psoriasis and metabolic
syndrome. It is worth noting that both psoriasis and
metabolic syndrome are associated with inflamma-
tion, characterized by increased proinflammatory cy-
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tokines, alteration of adipokine levels, lipid abnor-
malities, hyperuricemia or a prothrombotic state.
Therefore, it is considered that metabolic disturbances
may be connected to immunological abnormalities,
and that psoriasis may be considered as an immu-
nometabolic disease.
The exact mechanism which could explain the link
between psoriasis and metabolic disturbances has not
been precisely recognized. Therefore, further studies are
needed, designed to estimate the correlation between
biochemical markers of metabolic syndrome and psori-
asis, as well as to determine which of them could be
used to predict the development of metabolic syndrome
in patients with psoriasis. This research should cover
reference groups selected by age, gender and BMI. The
results of such studies could lead to a change of thera-
peutic strategies and improve psoriasis outcomes.
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